Pyridine

Pyridine

SCHEMBL6438460

CC(C#N)OP(=O)(O)O.c1ccncc1

nearest known ligand 0.31

Full drug profile on Sugi Atlas →

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.31
NAPRT Q6XQN6 1/20 0.31
TDP1 Q9NUW8 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22653 0.83
SCHEMBL28830260 0.81 SMPD1 (0.32) TSHR
SCHEMBL6998228 0.81 SMPD1 (0.32) TSHR
Pyridine SCHEMBL27519759 0.77 TDP1 (0.35) TSHRNAPRTTDP1
SCHEMBL8443992 0.74
SCHEMBL7913004 0.73 ALDH1A1 (0.35) TSHR
Pyridine SCHEMBL11782297 0.72 TSHR (0.38) TSHRNAPRTTDP1
Pyridine SCHEMBL29270057 0.71 TSHR (0.33) TSHRNAPRTTDP1
Phosphoric Acid Monomethyl Ester SCHEMBL21054851 0.71 TDP1 (0.45) TSHRNAPRTTDP1
Phosphoric Acid Monomethyl Ester SCHEMBL21054852 0.71 TDP1 (0.45) TSHRNAPRTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1085909-B1 A complex of alpha-fetoprotein (AFP) and a polyunsaturated fatty acid derivative for the treatment of immune deficiencies ARDENIA INVESTMENTS LTD (GI) 2005-12-28 EP disclosed
US-6599507-B2 Immunostimulation ARDENIA INVESTMENTS, LTD. (GI) 2003-07-29 US disclosed
EP-1161436-B1 Polyunsaturated fatty acid derivatives and their use in the treatment of cancer ARDENIA INVESTMENTS LTD (GI) 2003-06-25 EP disclosed
US-6403554-B2 Polyunsaturated fatty acid derivatives and their use ARDENIA INVESTMENTS LTD. (GI) 2002-06-11 US disclosed
EP-1161436-A1 POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE Ardenia Investments Ltd. (GI) 2001-12-12 EP disclosed
US-20010037032-A1 Polyunsaturated fatty acid derivatives and their use OASMIA PHARMACEUTICAL AB (SE) 2001-11-01 US disclosed
US-20010034324-A1 Composition for the treatment of immune deficiencies and methods for its preparation and use OASMIA PHARMACEUTICAL AB (SE) 2001-10-25 US disclosed
US-6274747-B1 COMPOUNDS CONTAINING A PHOSPHATE GROUP AND SECONDARY AMIDE GROUP; ANTICANCER AGENTS ARDENIA INVESTMENTS LTD. (GI) 2001-08-14 US disclosed
EP-1085909-A2 COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE Ardenia Investments Ltd. (GI) 2001-03-28 EP disclosed
WO-2000047589-A1 POLYUNSATURATED FATTY ACID DERIVATIVES AND THEIR USE ARDENIA INVESTMENTS LTD. (SE) 2000-08-17 WO disclosed
WO-1999065936-A2 COMPOSITION FOR THE TREATEMENT OF IMMUNE DEFICIENCIES AND METHODS FOR ITS PREPARATION AND USE ARDENIA INVESTMENTS LTD. (GI) 1999-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034324-A1 Composition for the treatment of immune deficiencies and methods for its preparation and use ALB, NAPEPLD, TTPA TSHR 3707/4885NAPRT 378/4885TDP1 2867/4885
US-20010037032-A1 Polyunsaturated fatty acid derivatives and their use RXRA, RXRB, LPAR2 TSHR 259/4885NAPRT 1038/4885TDP1 1383/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.